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Background: Gestational diabetes mellitus (GDM) is defined as glucose intolerance with its onset or first
recognition during pregnancy. Post-GDM women have a life-time risk exceeding 70% of developing type 2 diabetes
mellitus (T2DM). Lifestyle modifications reduce the incidence of T2DM by up to 58% for high-risk individuals.
Methods/Design: The Mothers After Gestational Diabetes in Australia Diabetes Prevention Program (MAGDA-DPP)
is a randomized controlled trial aiming to assess the effectiveness of a structured diabetes prevention intervention
for post-GDM women. This trial has an intervention group participating in a diabetes prevention program (DPP),
and a control group receiving usual care from their general practitioners during the same time period. The 12-
month intervention comprises an individual session followed by five group sessions at two-week intervals, and two
follow-up telephone calls. A total of 574 women will be recruited, with 287 in each arm. The women will undergo
blood tests, anthropometric measurements, and self-reported health status, diet, physical activity, quality of life,
depression, risk perception and healthcare service usage, at baseline and 12 months. At completion, primary
outcome (changes in diabetes risk) and secondary outcome (changes in psychosocial and quality of life
measurements and in cardiovascular disease risk factors) will be assessed in both groups.
Discussion: This study aims to show whether MAGDA-DPP leads to a reduction in diabetes risk for post-GDM
women. The characteristics that predict intervention completion and improvement in clinical and behavioral
measures will be useful for further development of DPPs for this population.
Trial registration: Australian New Zealand Clinical Trials Registry ANZCTRN 12610000338066
Keywords: Gestational diabetes, Post-natal, Lifestyle intervention, Type 2 diabetes preventionBackground
Type 2 diabetes (T2DM) and gestational diabetes mellitus
(GDM) are escalating problems worldwide. Depending on
the population studied, 1 to 14% of all pregnancies are
complicated by GDM [1]. This estimate may double if
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reproduction in any medium, provided the orPregnancy Study Groups (IDAPSG) recommended cri-
teria are implemented [2].
Gestational diabetes mellitus is defined as glucose in-
tolerance of variable severity with onset or first recogni-
tion during pregnancy [3]. Post-GDM women have a
life-time risk of developing T2DM exceeding 70% [4]. In
Australia, between 2005 and 2006, GDM was diagnosed
in 4.6% of hospital births, and the incidence increased
by 22% over 6 years from 3.6 per 100 pregnancy in
2000/01 to 4.4 per 100 pregnancy in 2005/06 [5]. Risk
factors for GDM include family history of diabetes, aged. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tion, and belonging to a high-risk ethnic group (for
example, Aboriginal and Torres Strait Islander, Pacific
Islander, South Asian, Middle Eastern) [6,7].
Pregnancies complicated by GDM have increased
incidence of fetal macrosomia. This in turn leads to an
increased risk of caesarean deliveries, maternal pre-
eclampsia, and neonatal complications including hypo-
glycemia, shoulder dystocia, and birth trauma [7].
Women with GDM also have a significantly increased
risk (by approximately 25% of absolute risk) of develop-
ing T2DM within 15 years relative to women without
GDM [8] and a 30 to 69% increased risk of developing
GDM in subsequent pregnancies [9]. GDM also puts
the child at risk, with the offspring of mothers with
GDM having an increased risk of obesity and abnormal
glucose metabolism during childhood, adolescence, and
adulthood [10].
In Australia, the prevalence of T2DM has more than
doubled since 1981, with 3.8% of Australians, almost
one million, having been diagnosed with T2DM in 2007
to 2008 [11]. It is also estimated that at least half of
those who have T2DM are undiagnosed, and so are un-
aware of their condition [12]. Currently, diagnosed dia-
betes is the second highest contributor to the Australian
burden of disease, responsible for 5.2% of disability ad-
justed life-years. It is estimated that by 2023, T2DM will
be the leading contributor, responsible for 8.6% of over-
all disease burden [13], resulting from the major mor-
bidity of diabetes complications. Diabetes also poses an
enormous economic burden, accounting for A$1.4 bil-
lion (or US$ 1.26 billion, approximate exchange rate A
$1 to US$0.9) in healthcare expenditure in 2003, which
is projected to increase to almost A$7 billion (US$6.3
billion) by 2033 [14].
Therefore, there is an urgent need to implement a
widespread and coordinated approach to prevent T2DM.
Several clinical trials have shown that lifestyle modifica-
tion with weight loss and moderate exercise can reduce
the incidence of T2DM by up to 58% for people at high
risk [15-17]. Indeed, these lifestyle modification pro-
grams have been shown to be even more effective than
drug treatment in clinical trials [7,16,18], and have a
lasting effect that is still evident eight years from the on-
set of intervention and four years after the active inter-
vention has ceased. The diabetes prevention program
conducted in the United States (US DPP) included 350
women with previous GDM [7]. The results showed a
greater conversion to diabetes for GDM than non-GDM
women; however, both groups responded to metformin
treatment and lifestyle interventions [7].
One way to approach this problem is target individuals
at high risk of developing diabetes. Previous studies such
as the US DPP and the Finnish prevention study [19]have targeted individuals with glucose dysregulation as
identified by an oral glucose tolerance test. A history of
GDM is one of the major risk factors in women who
should be targeted for preventing development of T2DM.Mothers After Gestational Diabetes in Australia study
The Mothers After Gestational Diabetes in Australia
(MAGDA) aims to develop and implement a macro-
level system change to reduce the risk of progression to
T2DM for women with previous GDM. The project
consists of four components: (1) a register to facilitate
appropriate follow-up after diagnosis of GDM; (2) an
intervention to reduce progression to T2DM; (3) a
health economics evaluation of the register and inter-
vention; and (4) an understanding of how to implement
the register and follow-up in general practice. This
paper presents the protocol for the intervention, a ran-
domized controlled trial (RCT) of the Mothers After
Gestational Diabetes in Australia Diabetes Prevention
Program (MAGDA-DPP). The MAGDA-DPP trial of-
fers an evidence-based structured lifestyle modification
group-based intervention for women who have had
GDM. The objectives of MAGDA-DPP are that the inter-
vention will result in favorable changes, relative to usual
care, in clinical, behavioral and patient-relevant outcome.
In addition, MAGDA-DPP aims to identify individual
characteristics predictive of successful outcome.Methods/Design
Study design
MAGDA-DPP is a prospective, open RCT to assess the
effectiveness of a structured diabetes prevention pro-
gram (DPP) for women who have had GDM. This trial
has an intervention group participating in a DPP and a
control group receiving usual care from their general
practitioners (GPs) during the same time period. Women
will be recruited from two Australian State capital cities,
Melbourne and Adelaide.
All women recruited into the study will be followed up
for 12 months. At baseline, the women will undergo an
assessment consisting of blood tests, anthropometric mea-
surements, and self-reported assessment of health status,
diet, physical activity, quality of life, depression and risk
perception. The intervention group will be assessed at
baseline, and at three and 12 months. The control group
will be assessed at baseline and 12 months.
The MAGDA-DPP intervention is coordinated by Deakin
University (Melbourne Campus) and is supported by a
‘Partnerships for Better Health’ Grant from the National
Health and Medical Research Council of Australia
(NHMRC). The project includes multiple study part-
ners, consisting of two state governments, three univer-
sities and two non-government organizations. Study
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provals are listed in Table 1.
Selection of participants
The inclusion criterion for women is diagnosis of GDM
in their most recent pregnancy, with GDM defined by
the Australasian Diabetes in Pregnancy Society (ADIPS)
criteria: fasting plasma glucose (FPG) of 5.5 mmol/L or
higher, and/or 2 hour glucose of 8.0 mmol/L or higher on
a 75 g oral glucose tolerance test (OGTT) [3], or a glucose
challenge test (GCT) result of 12.0 mmol/L or higher.
The exclusion criteria are: (1) pre-existing diabetes
(Type 1 or 2 diabetes mellitus); (2) cancer (not in remis-
sion); (3) severe mental illness; (4) substance abuse (illicit
drugs); (5) myocardial infarction in the preceding three
months; (6) difficulty with English; (7) involvement in an-
other post-natal intervention trial; and (8) pregnancy at
post-natal baseline testing or at any point during the 12
months of study involvement.
Once women diagnosed with GDM express interest in
the study, the recruiter (the MAGDA-DPP project man-
ager or research assistant) will conduct the first eligibil-
ity screening, generally prior to the women delivering
their babies. A subsequent post-natal screening will be
conducted at time of baseline OGTT, to exclude women
who have diabetes at that stage.
Recruitment process
Multiple recruitment strategies will be used for MAGDA-
DPP. The study will be promoted by mailed leaflets viaTable 1 MAGDA project study partners, recruitment sites and
Study partner/recruitment site (state) Ethics approval auth
Deakin University (VIC) Deakin University hum
Flinders University (SA) Southern Adelaide Clin
The University of Melbourne (VIC) NA
Department of Health (VIC) NA
South Australia Health (SA) South Australia Health
Diabetes Australia Victoria branch (VIC)/NDSS Deakin University hum
GP-Victoria NA
The Royal Women’s Hospital (Vic) The Royal Women’s Ho
Sunshine Hospital (VIC) Melbourne Health (201
Lyell McEwin Hospital (SA) The Queen Elizabeth H
human research ethics
ethics committee (04-1
Flinders Medical Centre (SA) South Australia Health
Aboriginal Health rese
human research ethics
Women’s and Children’s Hospital (SA) South Australia Health
Aboriginal Health rese
(SSA/13/WCHN/73)
Abbreviations: NA not applicable, NDSS National Diabetes Service Scheme, SA South
1Lead human research ethics committee for the overall project.
2Lead human research ethics committee in South Australia.the National Diabetes Services Scheme (NDSS) (using
data from the National GDM Register) [20] to women liv-
ing in relevant postcodes in Adelaide (South Australia)
and Melbourne (Victoria). Women will be recruited pre-
dominantly through participating hospitals, referrals from
private healthcare providers and retrospective database
mining of hospital records. Other specific recruitment ac-
tivities may be used in consultation with the diabetes edu-
cation service at each hospital. Women diagnosed with
GDM will be informed about the study by diabetes educa-
tors, either individually or in a group.
Prospective recruitment will take place at The Royal
Women’s Hospital and Sunshine Hospital in Melbourne
and Lyell McEwin Hospital in Adelaide. Because of late
participation in the study by Women’s and Children’s
Hospital and Flinders Medical Centre in Adelaide, retro-
spective as well as prospective recruitment will take
place at these hospitals only, allowing women diagnosed
with GDM after July 1, 2011 to participate in the study
(Table 1).
At the hospital recruitment sites, women newly diag-
nosed with GDM will be referred, if they agree, to the
MAGDA recruiter. Alternatively, potential participants
will be identified by their medical history or from the list
of newly diagnosed patients, with the assistance of the
clinic coordinator. Women will be approached by the
recruiter in the antenatal clinic waiting room or when
attending diabetes education group sessions. Patients
will receive a study outline and will be offered participa-
tion in the study. At the hospital site’s group diabetesrelevant ethics approvals
orities (reference number)
an research ethics committee (2010–005)1
ical Network human research ethics committee (330/10)
human research ethics committee (339/02/2013)
an research ethics committee (2010–005)1
spital (10/06)
0.008)
ospital/Lyell McEwin Hospital HREC (2011109)2; South Australia Health
committee (339/02/2013); South Australia Aboriginal Health research
0-331)
human research ethics committee (339/02/2013); South Australia
arch ethics committee (04-10-331); Southern Adelaide Clinical Network
committee (330/10); Southern Adelaide Health Service (SSA/12/SAC/170)
human research ethics committee (339/02/2013); South Australia
arch ethics committee (04-10-331); Women’s and Children’s Hospital
Australia, VIC Victoria.
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progression to T2DM and outline the study. Eligibility
screening will be carried out for all interested women,
and consent forms will be provided at the session or
mailed after the session. If a woman is not interested in
participating at first approach or withdraws at any other
stage of the study, the reasons for her decision will be
sought.
Consent
Eligible women will be given a Participant Information
and Consent Form (PI&CF) to review with the recruiter.
If there is inadequate time to review the PI&CF, a copy
will either be provided directly to the participants or
mailed to them along with a prepaid envelope in which
to return the completed consent form. If the consent
form is not received within four weeks, the recruiter willSeveral methods of recruitm
employed at each site.
Not interested. Ask why?
Recruiter will contact the patient to
more information & answer que
Not eligible. No further contact 
If no T2DM, proj
senior program m
randomize the w
If interested. 
Intervention
No further 
contact 
Figure 1 Recruitment flowchart.make contact with the woman. At three months postpar-
tum for all live births, the MAGDA-DPP recruiter will
follow up with a phone call to verify if an OGTT at six
to eight weeks postpartum has been performed. At three
months postpartum and onwards, if the woman does
not have diabetes, the study nurse/phlebotomist will
make contact to organize for baseline data collection.
Once the results of the baseline blood tests are known,
women with confirmed diabetes will be informed, re-
ferred to their nominated GP and excluded from the
study. If they do not have diabetes, they will be random-
ized into either the control or the intervention group.
The recruitment flowchart is shown in Figure 1.
Randomization
Block randomization will be implemented and separate
randomization lists for each ‘venue’ or ‘stratum’ will beent will be 
If eligible, recruiter will 
provide/send the patient PI&CF 
with prepaid envelope 
If T2DM, Senior 
Research Nurse will 
refer the women to 
GP. 
 provide 
stions
From 3 months postpartum, recruiter 
will follow up with a phone call. Check 
that 6-8 weeks postpartum OGTT has 
been done 
ect manager /
anager will 
omen
Check eligibility
Recruiter asks questions 
on diabetes status, cancer, 
severe mental illness, 
substance abuse, 
myocardial infarction, 
proficiency in English 
language.
If consent form not received within 
4 weeks, recruiter will contact the 
women.  
Consent form received
From 3 months post-partum 
study nurses will contact the 
woman to organise baseline 
data collection
Control
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will be imported into the current MAGDA management
database, which selects the next available sequence num-
ber for the venue/stratum. This sequence number will
be displayed, along with the assignment code (control or
intervention) to the user in the randomization office at
Deakin University.
Women will be randomized into either the interven-
tion or control arm after the baseline blood results have
been received by the MAGDA-DPP project manager. If
the woman does not have diabetes, the project manager
or senior program manager will randomize her using the
MAGDA-DPP management database. Each woman will
receive a letter with the outcome of her randomization
along with her baseline test results, and a copy will be
sent to her nominated GP.
Intervention
The theoretical framework of the MAGDA-DPP inter-
vention is based on the Health Action Process Approach
(HAPA), and supported by social cognitive theory [21,22]
and self-regulation theory [23-25], which has informed the
structuring of the program and activities in each session.
The intervention was based on the Life! program [26],
which was previously shown to be effective in affecting
change in diabetes risk factors. The theory driven compo-
nents of the program were enhanced and the content of
sessions tailored to reflect the issues that previous work
has shown to be of relevance to this population (for
example, sleep deprivation, post-natal depression). The
intervention delivery is driven by a facilitator’s manual that
outlines the core content and behavioral change processes
to be used in each session of the program. Fidelity of the
program will be established by assessment of the audio re-
cordings when the facilitator is delivering the sessions.
The intervention group will be offered a series of six
face-to-face sessions delivered by trained healthcare pro-
fessionals, with two additional follow-up telephone calls
at a later stage. Table 2 summarizes the core curriculum
of the sessions. The first session will be an individual ses-
sion carried out in the woman’s home, nominated com-
munity health center or Aboriginal health center. The
initial session will be followed by five group sessions held
at two week intervals and two subsequent phone calls at
three and six months after the final group session. Each
group session will be two hours long with up to 15 women
per group. The control group will continue with usual
care and be offered the intervention program after 12
months subject to timing or availability of MAGDA-DPP
courses. An indicative timeline from recruitment to com-
pletion of the follow-up is illustrated in Figure 2.
At the first individual session, the participant will be
provided with an intervention program handbook. The
intervention program aims to encourage participants toachieve the following five goals: (1) reduce fat intake (no
more than 30% of energy from fat); (2) decrease saturated
fat intake (no more than 10% of energy from saturated
fat); (3) increase fiber intake (at least 15 g per 1000 kcal);
(4) increase physical activity (at least 30 minutes of mod-
erate exercise per day); and (5) reduce body weight (at
least 5% of body weight reduction within 12 months).
Outcome assessment
At baseline and completion of the study (12 months
after baseline), primary (changes in diabetes risk) and
secondary (changes in cardiovascular disease risk factors,
psychosocial and quality of life measurements) outcome
will be assessed.
Primary outcome
The primary outcome is the change in diabetes risk, as
determined by changes in FPG, weight, or waist circum-
ference. A statistically significant change in any one of
these three endpoints will be regarded as evidence of a
change in diabetes risk. No adjustments to significance
levels will be made for multiple testing. These co-primary
outcome will be assessed at baseline and 12 months for all
women, and additionally at 3 months (or as soon as pos-
sible after the final group session) for the intervention par-
ticipants only.
Secondary outcomes
Changes in glucose (2 hour OGTT), fasting lipids, blood
pressure, depression, quality of life, physical activity and
diet are the secondary outcome, which will be assessed
at baseline and 12 months for all women.
Anthropometric measurements and laboratory testing
To ensure that the clinical measurements meet research
standards, measurements will be carried out by specially
trained study nurses/phlebotomist. All clinical tests will
follow the latest international recommendations from the
European Health Risk Monitoring protocol [27]. Blood
samples will be collected by the study nurse/phlebotom-
ist, and analyzed by Melbourne Pathology (Victoria) or
ClinPath (South Australia). Anthropometric measure-
ments including height, weight, waist and hip circum-
ference, and blood pressure will be taken. Women will
be asked to fast from 10 pm the night before their
appointment and venous samples will be drawn at the
appointment to analyze lipids (triglycerides, total chol-
esterol, low-density lipoprotein and high-density lipo-
protein cholesterol), HbA1c and glucose (fasting and 2
hour OGTT). Additional blood from women who consent
to having their blood stored will be bio-banked at −80°C
for further additional analyses.
For the intervention group only, at three months after
baseline testing or as soon as possible after the final
Table 2 MAGDA-DPP core curriculum and key contents of
the six sessions and two follow-up telephone calls
Session Topics covered
Individual session
(delivered in participant’s
home at >3 months
postpartum)
Introduction to DPP
Assessment of personal risk of developing
T2DM
Highlight the five program goals:
• Reduce weight by 5%
• Reduce total fat intake to < 30% daily
energy intake
• Reduce saturated fat intake to < 10%
daily energy intake
• Increase fiber intake to > 15 g per
1000 kcal
• Increase physical activity to at least 30
minutes moderate intensity physical
activity on at least 5 days per week
Build commitment to attend the program
by discussed perceived benefits and
importance of attending
Establish personal weight goal (current
weight minus 5%) for the after 3 months
Set physical activity goal
Group session 1 (held in
community venue within
1 month of individual
session)
Background to the program
What is diabetes?
Physical activity goal-setting: review of
progress with goal set at the individual
session
Fighting fat: saturated fat
• Benefits of reducing saturated fat intake
• Identify common sources of saturated
fats in foods and from food labels
• Practice modifying foods to reduce
saturated fat content
Saturated fat goal-setting
Group session 2 (held in
community venue 2
weeks after Group
session 1)
Review goals set, and set new activity goal
Fighting fat: total fat
• Benefits of reducing total fat intake
• Identify sources of dietary fat
• Self-assessment of current total fat intake
• Practice modifying foods to reduce total
fat content
Weight management
Total fat goal-setting
Group session 3 (held in
community venue 2
weeks after Group
session 2)
Review goals set, and set new activity goal
Filling up on fiber
• Benefits of increasing fiber intake
• Goals for daily fiber intake
• Self-assessment of current fiber intake
• Identify high-fiber foods
• Identify meal plans that are high in fiber
Table 2 MAGDA-DPP core curriculum and key contents of
the six sessions and two follow-up telephone calls
(Continued)
Family healthy eating (part 1)
• Healthier shopping activity
Healthy eating goal-setting (1)
Group session 4 (held in
community venue 2
weeks after Group
session 3)
Review goals set, and set new activity goal
Family healthy eating (part 2)
• Healthier family meal-planning
• Dealing with barriers to making healthier
choices
Mindful eating
Managing sleep
• Importance of good family sleep patterns
• Ways to improve sleep
Healthy eating goal-setting (2)
Group session 5 (held in
community venue 2
weeks after Group
session 4)
Review goals set and set new activity goal
Stress
• Impact of stress on feelings and
behaviors and health
• Identify sources of stress
• Identify unhelpful stress-management
strategies
• Discuss more helpful ways of managing
stress
Depression
• Identifying depression
• Impact of depression
• Identifying ways to manage depression
• Resources available for support
Relapse prevention
• Weight and energy balance
• Managing relapses
• Key strategies for maintaining a healthier
lifestyle
Long-term goal-setting
• Action-planning
• Problem-solving
• Rewards
Telephone follow-up 1
(3 months after Group
session 5)
Review of progress
Telephone follow-up 2
(6 months after Group
session 5)
Review of progress
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tests (except OGTT), and anthropometric measurements
of weight and waist circumference. All women who
complete this clinical testing will receive a standardized
Figure 2 Indicative timeline from recruitment to completion of follow-up.
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dence of high blood pressure or depression. A copy will
be sent to their nominated GP.
Self-report measures
Women will be asked to complete a comprehensive sur-
vey that includes demographic questions (at baseline
only); measures of health behavior including the Food Fre-
quency Questionnaire [28], the Active Australia Question-
naire [29], self-regulation [30] and self-efficacy for diet
and physical activity [23,24,31,32]; social support (Multidi-
mensional Scale of Perceived Social Support [33]); quality
of life (Assessment of Quality of Life, AQoL-8D) [34];
depression and suicidal ideation (Patient Health Question-
naire 9, PHQ9 [35]); and health status questions (includ-
ing demographics, smoking status, and history of diabetes,
myocardial infarction, cancer, and mental disorders) at
baseline and 12 months post-baseline.
If a woman scores 11 points or more on the PHQ9
and/or if she scores on the suicidal-ideation question
(question 9), this result will be discussed with her at the
time to establish whether she is aware of her depression
risk, and she will be advised to attend her GP for further
discussion and management. This will also be highlighted
in the results feedback letter to the woman and her GP.
A healthcare resource use cost diary will be given to all
women to record utilization of diabetes-related healthcareservices during the time from baseline to completion of
the study. The diary aims to collect costs associated with
activities related to GDM follow-up (such as weight
management and measurement of blood pressure, glucose
and lipid), and will include healthcare, time, and travel
costs. An additional purpose of the diary is to determine
any differences between the intervention and control
groups in seeking advice about lifestyle change and dia-
betes prevention.
Sample size and power calculation
For the estimation of sample size for two groups, using a
two-sided 5% significance level and 80% power, the total
number required will be 430 (215 in each arm). The
sample size calculation was based on the observed mean
change in FPG over 12 months in the Greater Green
Triangle Diabetes Prevention Program (GGT DPP) study
[36] and is powered to detect an effect size of 0.27 (as-
suming mean difference between intervention and con-
trol groups of 0.14 mmol/L and within group standard
deviation of 0.5 mmol/L). To allow for an estimated at-
trition rate of up to 25% (estimate based on the GGT
DPP), we will require a total sample of 574 (287 in each
arm). This sample size will provide sufficient power to
also analyze changes in weight and waist circumference.
The intention-to-treat (ITT) principle will be adhered
to, and sensitivity analysis will also be carried out.
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Participants’ blood test results will be uploaded onto
the Melbourne Pathology/ClinPath websites, which are
password-encrypted. In order to protect confidentiality,
the participant ID number and date of birth will be the
only identifying information available to the laboratory.
Melbourne Pathology will also post hard copies of the
pathology results to the study office (Deakin Univer-
sity), and ClinPath will send their hard copy results to
the study office in South Australia in secure envelopes
via ClinPath couriers.
Web-based survey forms will be used primarily to
collect information during the testing appointment, with
the paper-based system used as a back-up. Clinical mea-
surements will be recorded by the study nurse. All ques-
tionnaires are self-reported by the participating women,
and will use the participant ID number (on the front of
each form/questionnaire) as the identifier. Only the demo-
graphic questionnaire contains the participants’ contact
details, and this will be maintained separately from all of
the other information relating to each woman.
Data storage and management
All data will be stored on Deakin University eSolutions
servers (ISO 9000 compliant for security, access and
quality control) and the National eResearch Collabor-
ation Tools and Resources (NeCTAR) server. Data col-
lected by the research team will be transferred to locked
cabinets at the respective study offices, and 10% of hard
copy questionnaires will be randomly audited for quality
control.
Data analysis
Analyses will be performed using STATA version 12 or
later (Stata Corp., College Station, TX, USA) and the
ITT principle will be adhered to. Baseline characteristics
will be compared between the intervention and control
groups using χ2 tests, independent t-tests, and/or the
Wilcoxon rank-sum test, as appropriate. Primary and
secondary outcome (as described above) will be evalu-
ated using mixed models, treating ‘group’ as a between-
subject factor, and ‘time’ as a within-subject factor.
Two-sided tests will be used, with a level of P<0.05 de-
termining statistical significance.
A separate and parallel economic evaluation protocol
will be described elsewhere.
Discussion
Gestational diabetes mellitus is the strongest single popula-
tion predictor of T2DM. At least 20 to 50% of women who
have GDM will go on to develop diabetes within 28 years
[8,37], and women with GDM have a life-time risk exceed-
ing 70% of developing T2DM [4]. Lifestyle-modification
programs are effective in delaying or preventing diabetes inthe general high-risk population. Although there were
some post-GDM women in the US DPP [7], no interven-
tion program has previously been specifically designed and
tested for this group.
This study is necessary because it is important to
know if the MAGDA-DPP intervention leads to a reduc-
tion in diabetes risk in women with a history of GDM.
Defining the participants’ characteristics that predict at-
tendance and completion of the intervention and im-
provement in clinical and behavioral measures will be
useful for further development of DPPs for this popula-
tion in Australia and internationally.
Trial status
Recruitment in Melbourne (Victoria) commenced at The
Royal Women’s Hospital in January 2011, followed by
Sunshine Hospital in November 2011 and in Adelaide
(South Australia) at Lyell McEwin Hospital in January
2012. By June 4, 2013, 1,517 women diagnosed with GDM
have been approached during their clinic appointments at
the above three hospitals. Of these, 340 women have given
written consent, 219 have not yet returned their consent
form, 701 have declined to participate in the study and
257 were ineligible. Recruitment, both retrospectively and
prospectively, at Women’s and Children’s Hospital and
Flinders Medical Centre in Adelaide is expected to com-
mence in mid-2013.
Baseline testing commenced in July 2012 in Melbourne
(Victoria) and March 2013 in Adelaide (South Australia).
By June 4, 2013, 134 women had been randomized to
either the intervention or the control group. The first
MAGDA-DPP intervention group started in November
2012, and there have been six groups, four in Melbourne
(Victoria) and two in Adelaide (South Australia), initiated
since then.
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